WRIB 2026: What Bioanalytical Leaders Need to Know Now

Key takeaways from the 20th annual WRIB Conference

The 20th annual WRIB conference convened a cross-section of global stakeholders to examine the evolving bioanalytical landscape. This year’s discussions made one thing clear: the field is moving decisively toward science-driven, risk-based frameworks, with increasing regulatory alignment across regions and modalities.

These shifts reinforce the need to pair deep regulatory expertise with adaptable, fit-for-purpose assay strategies. Below are three of the consequential themes heard during the conference—and what they mean in practice.

1. Immunogenicity (ADA): From Prescriptive to Principle-Driven

Historically, immunogenicity testing has followed relatively rigid tiered frameworks. That paradigm is loosening.

  • Guidance vs. scientific justification Regulators are placing greater weight on why a method is appropriate, not just whether it adheres to legacy guidance structures.
  • Signal-to-noise over cut-point fixation Statistical cut-points alone are no longer sufficient. There’s a growing expectation to interpret ADA responses in terms of biological relevance and clinical context.
  • Confirmatory assays: no longer default The automatic inclusion of confirmatory tiers is being challenged. Reduced-tier or fit-for-purpose approaches are gaining acceptance when scientifically justified.
Sponsors must be prepared to defend assay design decisions holistically, integrating risk assessment, molecule characteristics and clinical context. Immunogenicity strategies are becoming less about checking boxes—and more about demonstrating relevance.

2. BMV vs. BAV: The Lines Are Blurring

A recurring—and significant—theme was the convergence between Bioanalytical Method Validation (BMV) and Biomarker Assay Validation (BAV).

  • From categorization to continuum Regulators are moving away from rigid PK vs. biomarker distinctions toward integrated validation frameworks.
  • Context of use is paramount Validation expectations increasingly hinge on how data will be used. Exploratory endpoints allow for more flexibility, while pivotal decision-making requires higher rigor and scrutiny.
  • Biomarkers under the microscope When tied to clinical decisions, biomarker assays are now subject to inspection-level expectations, similar to PK assays.
  • Fit-for-purpose remains central—but elevated The concept persists, but expectations around justification, documentation and lifecycle management are rising.
Organizations should expect greater regulatory scrutiny of biomarker assays, particularly in late-phase trials. A siloed approach to BMV vs. BAV is no longer viable—integration and consistency across assay strategies are now critical.

3. “Ask the Regulators”: A Clear Signal on Compliance Expectations

The standing-room-only “Ask the Regulators” session once again surfaced the most pressing friction points between industry and agencies.

  • Inspection readiness is non-negotiable Agencies emphasized preparedness not just at submission, but across the entire assay lifecycle.
  • Data integrity remains a top priority End-to-end traceability, audit trails and system controls are under increasing scrutiny.
  • Lifecycle validation is under the spotlight Validation is no longer a one-time event. Regulators expect ongoing performance monitoring, change control and system-level oversight.
  • Flexibility requires justification Agencies are open to novel approaches—but only when supported by clear, scientifically grounded rationale.
Engagement from FDA (CBER/CDER), EMA, MHRA, Health Canada, ANVISA and others highlighted a continued trend toward harmonization of expectations, even as regional nuances persist.

Looking ahead

WRIB 2026 underscored a pivotal shift—bioanalysis is no longer just a technical function; it is a strategic enabler of drug development and regulatory success.

If your organization is navigating these changes, now is the time to reassess whether your bioanalytical strategy is built for where the industry is going—not where it has been.

Shopping Cart